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Background: To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic
treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of
metastatic brain tumors in breast cancer patients.
Methods: Eight patients who participated in a phase II trial for breast cancer-induced refractory brain metastases were
enrolled and subjected to 4 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examinations that
evaluated Peak, Slope, iAUC60, and Ktrans before and after treatment. The treatment comprised bevacizumab on Day 1,
etoposide on Days 2–4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles. DCE-MRI was performed
before treatment and at 1 h, 24 h, and 21 days after bevacizumab administration.
Results: Values of the 4 DCE-MRI parameters reduced after bevacizumab administration. Compared with baseline
values, the mean reductions at 1 and 24 h were −12.8 and −24.7 % for Peak, −46.6 and −65.8 % for Slope, −27.9
and −55.5 % for iAUC60, and −46.6 and −63.9 % for Ktrans, respectively (all P < .05). The differences in the 1
and 24 h mean reductions were significant (all P < .05) for all the parameters. The generalized estimating
equation linear regression analyses of the 4 DCE-MRI parameters revealed that vascular normalization peaked
24 h after bevacizumab administration.
Conclusion: Bevacizumab induced vascular normalization of brain metastases in humans at 1 and 24 h after
administration, and the effect was significantly higher at 24 h than at 1 h.
Trial registration: ClinicalTrials.gov, identifier NCT01281696, registered prospectively on December 24, 2010
Keywords: Bevacizumab, DCE-MRI, Breast cancer, ChemotherapyBackground
Angiogenesis has been a therapeutic target in treating
several solid tumor types for decades [1–4]. Tumor vas-
cular normalization has recently been proposed as an
alternative to antiangiogenesis [5]. Tumor vasculature is
generally dysfunctional and comprises tortuous, dilated,* Correspondence: ttfshih@ntu.edu.tw
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sure and adversely affect drug delivery [6]. Animal stud-
ies have shown that antiangiogenic therapy can
normalize the abnormal structures and functions of
tumor blood vessels and improve drug delivery [7–9]. In
clinical settings, a combination of bevacizumab, an anti-
vascular endothelial growth factor (VEGF) monoclonal
antibody, and chemotherapy has been used for treating
metastatic breast cancer [10]. However, the modest
effect of bevacizumab observed in subsequent studies
resulted in the withdrawal of its indications by the Food
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and hypothesized that bevacizumab preconditioning and
subsequent chemotherapy is more effective than the
current standard treatment, wherein bevacizumab and
chemotherapy are concomitantly used. This hypothesis
was supported by an animal study in which chemother-
apy was administered 1–3 days after bevacizumab ad-
ministration; the chemotherapy penetration improved by
approximately 81 %, resulting in increased tumor growth
inhibition compared with that of concomitant chemo-
therapy and bevacizumab administration [12]. In
addition, bevacizumab administration 1 day before eto-
poside and cisplatin administration appeared highly ef-
fective in patients with breast cancer whose brain
metastases progressed after whole-brain radiotherapy
(WBRT) [13]. The central nervous system (CNS) tumor
objective response rate was 77.1 % according to the
volumetric criteria, and the median CNS progression-
free survival (PFS) and overall survival duration were 7.3
and 10.5 months, respectively [13]. Although the unex-
pected high efficacy strongly supports our hypothesis,
understanding whether vascular normalization occurs
immediately or 24 h after bevacizumab administration is
crucial. This information can facilitate identifying the
appropriate time for administering chemotherapeutic
agents following bevacizumab treatment in humans. Dy-
namic contrast-enhanced magnetic resonance imaging
(DCE-MRI) can facilitate noninvasive determination of
the contrast agent leakage kinetics from the vasculature
[14] and is a suitable technique for assessing bevacizu-
mab treatment response [15]. Therefore, we used DCE-
MRI for evaluating bevacizumab-induced vascular
responses in patients with metastatic brain tumors
originating from the breast.
Methods
Patient characteristics and clinical outcomes
This prospective study was approved by the institutional
review board of National Taiwan University Hospital,
and written informed consent was obtained from all
study participants before enrollment. Between January
2011 and January 2013, we conducted a multicenter
phase II study, in which patients with breast cancer
whose brain metastases progressed after WBRT were en-
rolled. The patients were intravenously administered
15 mg/kg of bevacizumab for 90 min on day 1, etoposide
at 70 mg/m2/day from day 2– to day 4, and 70 mg/m2 of
cisplatin on Day 2 (hereafter, the BEEP regimen) in a 21-
day cycle for a maximum of 6 cycles. The response as-
sessment criteria, including tumor objective response
rate and PFS, were described previously (registered at
ClinicalTrials.gov, identifier NCT01281696) [13]. Eight
patients agreed to participate in a serial DCE-MRI study,
the optional translational research stage of the phase IIstudy. The patients underwent 4 DCE-MRI examina-
tions as follows: before bevacizumab treatment, 1 ± 0.5 h
after the completion of bevacizumab administration
(2.5 h after starting bevacizumab application, which is
the time at which chemotherapeutic agents are conven-
tionally administered), 24 ± 2 h after starting bevacizu-
mab administration, and 21 days after the BEEP regimen
was administered.
Magnetic resonance imaging protocol
The participants fasted for 4 h and rested in the supine
position in the MR scanner. MRI was performed using a
3.0-T superconducting magnet (Magnetom Verio; Sie-
mens Medical Systems, Erlangen, Germany) with an 8-
channel head coil and applying the axial precontrast T1-
weighted turbo spin echo sequence (TR/TE, 4/1.2 ms;
flip angle, 150°; matrix, 232 × 256; field of view, 181 ×
200 mm; and slice thickness/interslice gap, 4/1.2 mm).
Subsequent quantification was performed using a 3D
gradient-echo sequence with isotropic resolution in all
three brain dimensions. A T1 brain map was initially
created using six flip angles (2, 5, 10, 15, 20, and 25°) to
determine the baseline precontrast values for the dy-
namic procedure. An MR pulse sequence of T1-
weighted volumetric interpolated brain examination
(TR/TE, 6/2.5 ms; flip angle, 18°; matrix, 232 × 256; field
of view, 208 × 230 mm; slice thickness/interslice gap, 3/
0 mm; temporal resolution per volume, 5.49 s; and z-
axis coverage, 104 mm with center on the target lesion)
was initiated 50 s before the injection of a standard dose
(0.1 mmoL/kg body weight) of gadobutrol (Gd-BT-
DO3A, Gadovist®, Bayer Schering, Berlin, Germany) at a
flow of 3 mL/s, followed by a 50-mL saline flush at the
same flow rate. Eighty volumes were acquired in a total
measurement time of 6 min and 23 s. Postcontrast axial
T1-weighted image sequences, which were identical to
the precontrast image sequences, were obtained after
DCE-MRI.
Tumor volumetric measurement
Tumor volumetric measurement was performed by an
experienced radiologist who was blinded to the treat-
ment status of the patients. All the enhanced lesions on
post-contrast T1-weighted images were outlined using a
volumetric approach, which outlined each enhancing
voxel on postcontrast scans and then summed the voxels
to calculate an overall lesion volume [16].
Data postprocessing
Postprocessing of all DCE-MRI data was performed
using a commercial software tool (MIStar; Apollo
Medical Imaging, Melbourne, Australia) for image
segmentation and coregistration [17]. The slice with
the largest diameter in a target lesion was selected
Table 1 Demography and clinical characteristics of patients (n = 8)
Characteristics Number Percent
Age
Median (range) 49.2 (35.7–71.8)
Histology Type
Invasive Ductal Carcinoma 8 100
Hormone Receptor Status
ER- and PR- 3 37.5
ER- and PR+ 4 50.0
ER+ and PR- 0 0
ER+ and PR+ 1 12.5
HER2 Expression
IHC 0-2+ and/or FISH - 3 37.5
IHC 2+ and FISH +, IHC 3+ 5 62.5
Hormonal and HER2 Status
Triple Negative 0 0.0
ER+ and HER2- 3 37.5
HER2+ 5 62.5
Molecular Subtype
Luminal A 3 37.5







Note: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2, IHC immunohistochemistry, FISH fluorescent in situ
hybridization, ECOG Eastern Cooperative Oncology Group
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by an experienced radiologist to obtain a time-signal
intensity curve.
Three semiquantitative parameters (Peak, Slope, and
iAUC60) were determined [17, 18]. Peak was defined as
(SImax − SIbase)/SIbase × 100, where SIbase was the average
baseline signal before the inflow of the contrast agent in
the arteries and SImax was the maximal value of the first
pass of the time-signal intensity curve. Slope was derived
from the steepest part of the first-pass portion of the
time-signal intensity curve. iAUC60 (mM · s) was the ini-
tial area under the time-signal intensity curve within
60 s of contrast inflow. Ktrans (1/min) was derived using
a bicompartmental model of Tofts et al. [19] and
through nonlinear fitting of individual time-signal in-
tensity curves. These parameters were automatically
calculated pixel by pixel from the fitted curve. To
measure the arterial input function, a region of inter-
est was defined in the middle cerebral artery. Ktrans
was related to the permeability surface product per
unit volume of extravascular extracellular space in
nonflow-limited situations.
Statistical analysis
Data are expressed as means and standard deviations
(SDs). In univariate analysis, the relative changes in
DCE-MRI parameters at 1 h, 24 h, and 21 days were
determined by comparing the final parameter values
with baseline values. Subsequently, multivariate ana-
lysis was performed by fitting multiple linear regres-
sion models to identify predictors of the relative
changes in the 4 DCE-MRI parameters over time.
Generalized estimating equations (GEEs) [20] were
used for determining the correlations between re-
peated measurements of each patient. The statistical
power of the data was analyzed using repeated-
measurement ANOVA. A 2-sided P ≤ .05 was consid-
ered statistically significant. Statistical analysis was
performed using SPSS 15.0 (SPSS Inc., Chicago, Illi-
nois, USA) and R 3.0.2 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Patient characteristics, tumor response, and clinical
outcomes
The median age of the participants was 49.2 years
(range: 35.7–71.8 y). Three patients were estrogen recep-
tor (ER) positive and human epidermal growth factor re-
ceptor 2 (HER2) negative, one patient was ER and HER2
positive, and four patients were ER negative and HER2
positive (Table 1). The median number of extra-CNS
metastasis sites and BEEP protocol treatment cycles was
2.5 (range: 1–3) and six (range: 3–6), respectively. CNS
lesions of all patients exhibited partial responses at9 weeks, and five patients subsequently underwent MRI
to confirm the CNS objective response. With a median
follow-up of 16.8 months, the median CNS-specific PFS
time was 9.1 months (95 % confidence interval [CI],
4.7–13.5), and the overall survival time was 10.7 months
(95 % CI, 7.8–18.8). The mean CNS tumor size at the
baseline was 29.5 ± 37.4 cm3. The average change in the
lesion size from baseline was −43.6 ± 18.5 % at
21 days, −56.2 ± 12.1 % at 9 weeks (N = 8), and −66.7
± 16.7 % at 18 weeks (N = 6).
Change in dynamic contrast-enhanced magnetic
resonance imaging parameters in the first cycle of BEEP
Compared with the baseline values, the reductions in
the mean percentage change of all 4 DCE-MRI parame-
ters at 1 h, 24 h, and 21 days were significantly different
from zero (Table 2, Figs. 1 and 2), which indicated de-
creased gross angiogenesis within tumors after the BEEP
treatment. Moreover, the reductions in the mean
Table 2 Relative changes in DCE-MRI parameters compared
with baseline values at 1 h, 24 h, and 21 days after the first dose
of bevacizumab in eight patients with breast cancer with brain
metastases
Parameters Baseline Δ1 h(%) Δ24 h(%) Δ21 Days(%)
Peak 223.3 ± 47.2 −12.8 ± 4.6 −24.7 ± 7.9 −27 ± 8.6
Slope 1.5 ± 1.1 −46.6 ± 26.5 −65.8 ± 20.6 −52.8 ± 27.7
iAUC60 49820 ± 31258 −27.9 ± 15 −55.5 ± 11.1 −58.1 ± 15
Ktrans
(min-1 x 1000)
858.1 ± 1194.7 −46.6 ± 27.6 −63.9 ± 31.2 −78.2 ± 23.9
Data are presented as the mean ± standard deviations (SD). The Wilcoxon
signed-rank test had P < .01 compared with the baseline DCE-MRI data
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significantly higher at 24 h than at 1 h, which sug-
gested higher effect of vascular normalization of beva-
cizumab at 24 h than at 1 h. The differences between
Peak, Slope, iAUC60, and Ktrans values at 1 and 24 h
were −13.4 ± 10.1 % (P = .023), −31.7 ± 24.0 % (P = .008),
−30.0 ± 20.0 % (P = .008), and −40.6 ± 30.6 % (P = .023),
respectively, as per the Wilcoxon signed-rank test. How-
ever, the differences in the mean percentage change be-
tween 24 h and 21 days were nonsignificant for all 4
parameters (P > .05). The GEE linear regression analyses
for the 4 DCE-MRI parameters indicated that the extentFig. 1 A 75-year-old patient with breast cancer with a single brain metasta
image (T1WI) and DCE-MRI parameter maps (Peak, Slope, iAUC60, and Ktrans
and 21 days after the first cycle of BEEP regimen, respectivelyof vascular normalization was maximal at 24 h among
three time points (1 h, 24 h and 21 days) after bevacizu-
mab administration.
The repeated-measurement ANOVA analysis for the
percentage changes of these repeated measurements
(percentage changes between pretreatment and 1 h,
between pretreatment and 24 h, and between pretreat-
ment and 21 days) were significantly different (P < .01
for Greenhouse-Geisser and Huynh-Feldt tests) with
high statistical power (> .9) for Peak, iAUC60, and Ktrans
but not for slope (P > .05). The results suggested that
DCE-MRI parameters were helpful to evaluate serial
changes of tumor angiogenesis after anti-angiogenic
agents with high statistical power.Discussion
We used DCE-MRI for evaluating bevacizumab-induced
tumor vascular responses in humans. All DCE-MRI pa-
rameters exhibited significant reductions as early as 1 h
after the completion of bevacizumab administration,
which is the time at which chemotherapeutic agents are
conventionally administered. However, maximal reduc-
tion was observed at 24 h. Thus, bevacizumab-induced
vascular normalization is time dependent, andsis had a partial response after 3 BEEP regimen cycles. T1-weighted
) of the metastatic tumor in the right frontal lobe at baseline, 1 h, 24 h,
Fig. 2 Mean percentage changes of DCE-MRI parameters at 1 h, 24 h, and 21 days compared with baseline values
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therapy may substantially enhance cytotoxic activity by
increasing drug delivery to the tumor tissue.
The potential mechanisms underlying DCE-MRI
parameter changes are reduction in tumor permeabil-
ity, perfusion, or volume through effective administra-
tion of cytotoxic agents. Because only bevacizumab
was administered on the first day, the reduction from
the baseline to 24 h can solely be attributable to the
bevacizumab effect. Studies have indicated that vascu-
lar normalization is a major outcome of bevacizumab
use, and the breast tumor is unlikely to shrink after
sole bevacizumab treatment [12, 21]. Therefore, the
change in DCE-MRI parameters from the baseline to
24 h most likely resulted from the normalization of
tumor vasculature rather than tumor mass change. By
contrast, the parameter changes on Day 21 may have
resulted from a combination of the antiangiogenesis
effect of bevacizumab and the antitumor effect of
cytotoxic agents. These complex effects may explain
why the differences in the mean percentage changes
of the 4 parameters between 24 h and 21 days were
nonsignificant.
We used three semiquantitative model-free parameters
(Peak, Slope, and iAUC60) to evaluate brain tumor perfu-
sion [22]. Peak was the concentration of the contrast
agent in the intravascular and extravascular extracellular
spaces and indicated the sum of the vessel density and
permeability factors [23]. Slope indicated the concentra-
tion of the contrast agent in the intravascular space and
can be determined according to tissue vascularization,
perfusion, and capillary permeability [19, 24]. iAUC60
was correlated with blood flow, vessel permeability, andinterstitial space [25]. These model-free metrics are not
based on specific physiology and most likely represent a
combination of tumor blood flow, blood volume, and
permeability [18]. By contrast, the model-based quantita-
tive parameter, Ktrans, reflects the rapid transport of the
contrast agent from the plasma to the extravascular
space and is a function of both permeability and vessel
surface area [26]. The consistent decrease in all 4 DCE-
MRI parameters from the baseline to 24 h further vali-
dated our vascular normalization hypothesis. In addition,
based on our data, Ktrans was the best parameter for
clinical use among 4 DCE-MRI parameters because its
relative change was larger than other three parameters
after antiangiogenic treatment, and thus may be more
sensitive to detect vascular normalization and treatment
response.
Ktrans values facilitate evaluating the response to anti-
angiogenic agents, predicting tumor recurrence or pro-
gression, and determining the optimal time at which the
blood–brain barrier opens to the maximum extent dur-
ing treatment [27–29]. Ktrans is dependent on both the
permeability of capillaries and blood flow in the tumor
tissue. When the capillary permeability is high, Ktrans is
equal to the blood plasma flow per unit volume of tissue,
whereas when the blood flow is high, Ktrans is equal to
the product of the permeability and the surface area of
the capillary vascular endothelium [30]. Thus, Ktrans
may be highly dependent on blood flow because of the
high permeability of the disorganized vasculature in
untreated tumors. However, this parameter becomes
permeability dependent after bevacizumab treatment
because one consequence of vascular normalization is
increased blood flow.
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1 day before etoposide and cisplatin administration was
highly effective in treating patients with breast cancer
whose brain metastases progressed after WBRT [13].
Although our study did not enroll patients who received
concurrent chemotherapy with bevacizumab for com-
parison, we compared our results with those of Lin et al.
[31], who used a conventional dosing schedule, in which
carboplatin was administered immediately after bevaci-
zumab administration in breast cancer patients with
brain metastasis. The baseline condition of patients,
administration of whether other concomitant anticancer
drugs, and treatment duration differed between these
two studies. Lin et al. recruited only patients with an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of ≤2, and 87 % patients were ECOG 0–1. In
our study, 31 % of the patients had an ECOG of 3, and
23 % were ECOG 2, suggesting the difference in the
baseline tumor burden between these 2 studies. In Lin
et al., 22.6 % patients did not receive prior WBRT,
whereas 100 % of our patients received prior WBRT and
their brain tumors progressed after WBRT. In Lin et al.,
protocol treatment was continued until disease progres-
sion, whereas in our study, patients only received a max-
imum of 6 cycles (4 months) of protocol treatment
because of budget limitation. All HER2-positive patients
received trastuzumab in addition to bevacizumab and
carboplatin in the study of Lin et al., whereas none of
the HER2-positive patients in our study received trastu-
zumab during the 6 cycles of the BEEP regimen. The
overall results revealed that compared with concurrent
use, our study achieved a higher tumor response and
longer PFS with sequential use in patients with breast
cancer, even though our patient group seemed to have
more advanced disease status than that of Lin et al. Add-
itional confirmatory studies are necessary for direct
comparison of the efficacy between bevacizumab pre-
treatment 1 day before chemotherapy and immediate
sequential use of bevacizumab and chemotherapy in
patients with cancer.
To investigate the enhancement of drug delivery to the
CNS by bevacizumab-induced vascular normalization, we
measured the etoposide concentration in the cerebro-
spinal fluid (CSF); however, we found that bevacizumab
exerts no significant effects on CSF drug concentrations
[32]. Microdialysis is used for measuring drug concentra-
tions in the brain parenchyma; however, this procedure
cannot be readily used in clinical trials because of ethical
reasons [32]. The assumptions that CSF readily equili-
brates with brain interstitial fluid and CSF drug concen-
trations reflect drug concentrations in the brain
parenchyma have remained debatable. The choroid
plexus, which regulates drug transfer into the CSF from
the blood, and the brain capillary endothelium, whichregulates drug transfer into the interstitial fluid from the
blood, comprise completely different epithelial or endo-
thelial barriers. Studies have demonstrated different trans-
porter expression profiles in the blood–CSF and the
blood–brain barriers, supporting the opinion that the drug
concentration in the CSF can significantly deviate from
that in the brain parenchyma [33, 34].
Positron emission tomography (PET) with 18-
fluorodeoxyglucose (18F-FDG) can evaluate tumor
metabolism and is applied for diagnosis, staging and
monitoring of cancer. 18F-FDG has been evaluated as
imaging biomarker that can predict and assess
responses to various types of therapies including con-
ventional chemotherapeutic drugs and newer targeted
anti-cancer therapies in various tumor types [35]. For
example, by dynamic 18F-FDG PET analyses, treatment
with bevacizumab was shown to reduce both the tumor
perfusion and metabolism 24 h post-treatment in triple-
negative breast cancer xenografts [36]. FDG uptake was
also prognostic of response to bevacizumab-based therapy
in recurrent high-grade glioma [37]. Recently, hybrid
PET/MR systems provide advantages of combined im-
aging of brain tumor metabolism and perfusion, and may
offer complementary information on tumor biology and
monitor changes after treatment [38].
This study had several limitations. First, the sample
size was small. Although there were only eight patients,
concerns regarding lack of power usually arise when
known or plausible results are not confirmed or not de-
tected in statistical testing, which was not the case in
this study. All eight patients exhibited consistent and
significant changes after the first cycle of bevacizumab
administration. Second, we measured the DCE-MRI
parameters only in the largest target tumor. We assumed
that the perfusion changes were maximum in larger
tumors than in smaller tumors after chemotherapy, and
we compared the same tumor longitudinally because
considering multiple tumors involves high variability.
Third, no pathological specimen was available for direct
histological examination of the change in the vasculature
and interstitial pressure after bevacizumab treatment at
different time events in our study. A recent study
reported that the addition of bevacizumab to chemo-
therapy in patients with triple-negative breast cancer
significantly increases pathological complete response
rates [39]. A study that correlates DCE-MRI parameters
with pathological response rates after bevacizumab
administration may facilitate delineating the relationship
between vascular normalization and treatment effect.
Forth, Willett et al. found a significant increase in tumor
cell apoptosis at day 12 after bevacizumab administra-
tion [40, 41] in rectal cancer patients, but we did not
perform DCE-MRI at day 12 due to concern of MR con-
trast agent dose by our institutional review board. In
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underlying mechanisms of antivascular effect of bevaci-
zumab [42–44]. For examples, we may use plasm soluble
vascular endothelial growth factor-1 [44] to evaluate the
change of tumor oxygenation before and after bevacizu-
mab treatment and correlate this potential biomarker
with DCE-MRI parameters.
Conclusion
In conclusion, after anti-VEGF therapy with bevacizu-
mab, vascular normalization can occur as early as 1 h
after bevacizumab administration, and the effect is more
prominent after 24 h. Our study strongly indicated that
pretreatment with bevacizumab for a long duration can
enhance the efficacy of chemotherapy compared with
the conventional concurrent use of bevacizumab and
chemotherapy. Additional studies are warranted to
determine the optimal time for administering antiangio-
genesis therapy and chemotherapy in clinical practice.
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